2012 Vuelta a España, Stage 1 to Stage 11

Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort

Retrieved on: 
Thursday, November 10, 2022
Lymphatic system, Forward-looking statement, 2012 Vuelta a España, Stage 1 to Stage 11, ONC, DKG, Convention center, Pancreatic cancer, MPH, University of Ulm, PDAC, Annual general meeting, Interim, Immunotherapy, Research, Neoplasm, Travel, Boston Convention and Exhibition Center, KOL, COVID-19, Beth Israel Deaconess Medical Center, Goblet cell, Cancer, CEACAM6, PD-L1, NASDAQ, Pelareorep, Patient, Safety, Securities Exchange Act of 1934, Time, Oncology, Biomarker, Company, Science, AB, Clinical trial, Stage 2, Poster, Society for Immunotherapy of Cancer, Biotechnology, TSX, DOI, CBR, LINK, ORR, Phenotype, Regulation, SITC, AIO, Pharmaceutical industry, Risk management, Medical imaging, Oncolytics Biotech

SAN DIEGO, Calif and CALGARY, AB, Nov. 10, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort. Patients in this cohort are treated with the combination of pelareorep, Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel. The updated data are featured in a poster presentation at the ongoing Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA.  

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort.
  • Patients in this cohort are treated with the combination of pelareorep, Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel.
  • Objective response rate (ORR) and clinical benefit rate (CBR) in GOBLET's PDAC cohort (n=13) were 69% and 85%, respectively, asof the SITC poster's data cutoff date (October 12, 2022).
  • We were particularly excited to see a partial response deepen into a confirmed complete response as of the latest data cut, since this further indicates potentially durable anti-cancer effects from the combination therapy."

Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort

Retrieved on: 
Thursday, November 10, 2022
Lymphatic system, Forward-looking statement, 2012 Vuelta a España, Stage 1 to Stage 11, ONC, DKG, Convention center, Pancreatic cancer, MPH, University of Ulm, PDAC, Annual general meeting, Interim, Immunotherapy, Research, Neoplasm, Travel, Boston Convention and Exhibition Center, KOL, COVID-19, Beth Israel Deaconess Medical Center, Goblet cell, Cancer, CEACAM6, PD-L1, NASDAQ, Pelareorep, Patient, Safety, Securities Exchange Act of 1934, Time, Oncology, Biomarker, Company, Science, AB, Clinical trial, Stage 2, Poster, Society for Immunotherapy of Cancer, Biotechnology, TSX, DOI, CBR, LINK, ORR, Phenotype, Regulation, SITC, AIO, Pharmaceutical industry, Risk management, Medical imaging, Oncolytics Biotech

SAN DIEGO, Calif and CALGARY, AB, Nov. 10, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort. Patients in this cohort are treated with the combination of pelareorep, Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel. The updated data are featured in a poster presentation at the ongoing Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA.  

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort.
  • Patients in this cohort are treated with the combination of pelareorep, Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel.
  • Objective response rate (ORR) and clinical benefit rate (CBR) in GOBLET's PDAC cohort (n=13) were 69% and 85%, respectively, asof the SITC poster's data cutoff date (October 12, 2022).
  • We were particularly excited to see a partial response deepen into a confirmed complete response as of the latest data cut, since this further indicates potentially durable anti-cancer effects from the combination therapy."

Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Lymphatic system, Science, International, Boston Convention and Exhibition Center, DKG, Pelareorep, Stage 2, AIO, Securities Exchange Act of 1934, Interim, Travel, Clinical trial, DOI, SITC, Convention center, Company, Neoplasm, Journal, Immunotherapy, TSX, Phenotype, Cancer, Forward-looking statement, AB, Society, Patient, ORR, Investor relations, Progression-free survival, Research, CEACAM6, KOL, PDAC, LINK, Biotechnology, Breast, COVID-19, Annual general meeting, Pancreatic cancer, 2012 Vuelta a España, Stage 1 to Stage 11, Survival, Society for Immunotherapy of Cancer, MSI, Anal cancer, Time, JITC, Goblet cell, Safety, Biomarker, ONC, Poster, Standard of care, Regulation, NASDAQ, Roche, Oncology, Birth control, Pharmaceutical industry, Medical imaging, Oncolytics Biotech

(NASDAQ: ONCY) (TSX: ONC) today reported interim results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort in an abstract published as part of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today reported interim results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort in an abstract published as part of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
  • "Further, PD-(L)1 inhibitors only benefit fewer than one percent of pancreatic cancer patients classified as MSI-high.
  • Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc., commented, "GOBLET's interim results represent a crucial clinical milestone, providing robust proof-of-concept in a difficult-to-treat indication.
  • Alongside this potential PDAC opportunity, Oncolytics continues to advance pelareorep towards a registration study in metastatic breast cancer.

Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Lymphatic system, Science, International, Boston Convention and Exhibition Center, DKG, Pelareorep, Stage 2, AIO, Securities Exchange Act of 1934, Interim, Travel, Clinical trial, DOI, SITC, Convention center, Company, Neoplasm, Journal, Immunotherapy, TSX, Phenotype, Cancer, Forward-looking statement, AB, Society, Patient, ORR, Investor relations, Progression-free survival, Research, CEACAM6, KOL, PDAC, LINK, Biotechnology, Breast, COVID-19, Annual general meeting, Pancreatic cancer, 2012 Vuelta a España, Stage 1 to Stage 11, Survival, Society for Immunotherapy of Cancer, MSI, Anal cancer, Time, JITC, Goblet cell, Safety, Biomarker, ONC, Poster, Standard of care, Regulation, NASDAQ, Roche, Oncology, Birth control, Pharmaceutical industry, Medical imaging, Oncolytics Biotech

(NASDAQ: ONCY) (TSX: ONC) today reported interim results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort in an abstract published as part of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today reported interim results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort in an abstract published as part of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
  • "Further, PD-(L)1 inhibitors only benefit fewer than one percent of pancreatic cancer patients classified as MSI-high.
  • Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc., commented, "GOBLET's interim results represent a crucial clinical milestone, providing robust proof-of-concept in a difficult-to-treat indication.
  • Alongside this potential PDAC opportunity, Oncolytics continues to advance pelareorep towards a registration study in metastatic breast cancer.

Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
Time, Pancreatic cancer, ONC, Neoplasm, TSX, SITC, NASDAQ, Patient, Biotechnology, Phenotype, Research, Annual general meeting, Cancer, Immunotherapy, Convention center, Stage 2, Boston Convention and Exhibition Center, Company, Society, Pelareorep, ORR, Securities Exchange Act of 1934, 2012 Vuelta a España, Stage 1 to Stage 11, Safety, 2021 Essex County Council election, KOL, Clinical trial, CEACAM6, Forward-looking statement, Lymphatic system, Travel, COVID-19, AB, Society for Immunotherapy of Cancer, Biomarker, Poster, Regulation, Pharmaceutical industry, Communications satellite, Interior design, Medical imaging, Oncolytics Biotech

SAN DIEGO, and CALGARY, AB, Oct. 5, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 – 12, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 12, 2022.
  • Additional details on the abstracts and corresponding poster presentations are shown below.
  • Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
Time, Pancreatic cancer, ONC, Neoplasm, TSX, SITC, NASDAQ, Patient, Biotechnology, Phenotype, Research, Annual general meeting, Cancer, Immunotherapy, Convention center, Stage 2, Boston Convention and Exhibition Center, Company, Society, Pelareorep, ORR, Securities Exchange Act of 1934, 2012 Vuelta a España, Stage 1 to Stage 11, Safety, 2021 Essex County Council election, KOL, Clinical trial, CEACAM6, Forward-looking statement, Lymphatic system, Travel, COVID-19, AB, Society for Immunotherapy of Cancer, Biomarker, Poster, Regulation, Pharmaceutical industry, Communications satellite, Interior design, Medical imaging, Oncolytics Biotech

SAN DIEGO, and CALGARY, AB, Oct. 5, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 – 12, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 12, 2022.
  • Additional details on the abstracts and corresponding poster presentations are shown below.
  • Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022

Retrieved on: 
Monday, July 11, 2022
Physician, SAN, Safety, Private Securities Litigation Reform Act, CNTB, Adult, EASI, Terminology, CEO, CDE, Disease, 2012 Vuelta a España, Stage 1 to Stage 11, NDA, Atopic dermatitis, Entrepreneurship, National Medical Products Administration, Company, Ulcerative colitis, Asthma, IGA, Anti-inflammatory, Prevalence, Time, Patient, Connect, GLOBE, Center, AD, SEC, Inflammation, Itch, Area studies, Antibody, Pharmaceutical industry, Medical device, Vaccine

SAN DIEGO and TAICANG, SUZHOU, China, July 11, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”) today announced it has been informed by the Center for Drug Evaluation of the National Medical Products Administration (CDE), that it can conduct primary analysis of its ongoing pivotal trial for its lead product candidate CBP-201 to treat adult patients with moderate-to-severe atopic dermatitis (AD) based on the 255 patients already enrolled. As a result, Connect Biopharma plans to report this trial’s top-line results by year-end, earlier than originally planned.

Key Points: 
  • As a result, Connect Biopharma plans to report this trials top-line results by year-end, earlier than originally planned.
  • We plan to use the results from this PRC-specific trial, if positive, to initiate pre-NDA discussions with the CDE.
  • In addition, the projected timeline of the Companys global Phase 3 program in moderate-to-severe AD remains unchanged including to enroll the first patient by the end of 2022.
  • CBP-201 is also being evaluated in a China-specific pivotal trial in adults with moderate-to-severe AD (NCT05017480).

DGAP-News: MagForce AG: MagForce USA, Inc. has Received FDA's Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Ther

Retrieved on: 
Friday, November 5, 2021
MagForce, Safety, Boxer Protocol, Prostatectomy, Cancer, COVID-19, CTV, Neoplasm, Clinical trial, Prostate cancer, CEO, Frankfurt Stock Exchange, Degenerative disease, Heat, MF6, Food, Brain, Technology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nanomedicine, ISIN, Company, Review, 2012 Vuelta a España, Stage 1 to Stage 11, Patient, Group, Risk, FDA, EU, Medical imaging, Medical device, Pharmaceutical industry

Patient screening procedures, and enrollment of eligible patients, as well as treatments are being expedited at MagForce's NanoTherm treatment centers.

Key Points: 
  • Patient screening procedures, and enrollment of eligible patients, as well as treatments are being expedited at MagForce's NanoTherm treatment centers.
  • "We are very pleased that the FDA has greenlighted the final clinical trial protocol and we can now commence with Stage 2b of our pivotal US study.
  • The Stage 2b of the single-arm pivotal study is planned to evaluate the use of NanoTherm ablation for the treatment of prostate cancer patients with intermediate grade lesions.
  • The trial is designed to demonstrate that the NanoTherm therapy system can focally ablate targeted prostate cancer lesions with minimal side effects.

First Quantum Minerals Reports Third Quarter 2021 Results

Retrieved on: 
Tuesday, October 26, 2021
Sentinel, Safety, EBITDA, 2012 Vuelta a España, Stage 1 to Stage 11, Government, Travel, Workforce, Copper, TSX, Gold, AISC, Â, Company, Investment, CEO, Nickel, COVID-19, Health, GLOBE, Ravensthorpe, Sale, Lithium, Coal, Iron ore

TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- First Quantum Minerals Ltd. (“FQM” or the “Company”) (TSX: FM) today reported results for the three and nine months ended September 30, 2021. The Company reported, for the three months ended September 30, 2021 (“Q3”), comparative earnings1 of $197 million ($0.29 per share1), net earnings attributable to shareholders of the Company1 of $303 million ($0.44 per share1) and cash flows from operating activities of $703 million ($1.02 per share1).

Key Points: 
  • TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- First Quantum Minerals Ltd. (FQM or the Company) (TSX: FM) today reported results for the three and nine months ended September 30, 2021.
  • Total copper production for the third quarter was 209,859 tonnes, up from 199,689 tonnes in Q2 2021.
  • Sentinel delivered its best quarter of the year, producing 59,931 tonnes of copper, a 10% increase from the preceding quarter.
  • Total gold production for the quarter was 78,124 ounces, a 4% decrease from Q2 2021.

DGAP-News: MagForce AG: MagForce USA, Inc. has Received FDA's Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System

Retrieved on: 
Wednesday, October 13, 2021
ISIN, Approval, 2012 Vuelta a España, Stage 1 to Stage 11, Trial of the century, Risk, EU, MagForce, Heat, Food, Prostate cancer, Boxer Protocol, Prostatectomy, Brain, Safety, Cancer, Frankfurt Stock Exchange, FDA, Technology, Review, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Condition, MF6, Documentation, Group, CTV, Patient, Clinical trial, Nanomedicine, Medical imaging, Medical device

MagForce AG: MagForce USA, Inc. has Received FDA's Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System

Key Points: 
  • MagForce AG: MagForce USA, Inc. has Received FDA's Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
    The issuer is solely responsible for the content of this announcement.
  • MagForce is pleased that the FDA's conditions include using the final protocol in Stage 2b with targeted biopsy to assess effectiveness.
  • MagForce believes the FDA conditions are reasonable, and files the necessary documentation with the authority.
  • The trial is designed to demonstrate that the NanoTherm therapy system can focally ablate targeted prostate cancer lesions with minimal side effects.